ReviewCurrent treatment options in oncology2017
Desmoid-Type Fibromatosis: Who, When, and How to Treat.
Review in Current treatment options in oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.
- Surgical management of abdominal desmoids: a systematic review and meta-analysis.Irish journal of medical science · 2023Pooled it
- Clinicopathologic Study of Calcifying Fibrous Tumor Emphasizing Different Anatomical Distribution and Favorable Prognosis.BioMed research international · 2019Trial
- Genotype-guided conservative management of mesenteric desmoid tumors: A case report of intermediate-region APC mutations.Medicine · 2026Article
- Case Report: Two rare cases of aggressive fibromatosis originating in the intestinal tract.Frontiers in oncology · 2026Article
- Intranodal palisaded myofibroblastoma shows a unique epigenetic profile-first molecular study of their epigenetic and copy number variation profile.Virchows Archiv : an international journal of pathology · 2025Article
- Mandibular versus Maxillary Desmoplastic Fibroma: A Pooled Analysis of World Literature and Report of a New Case.European journal of dentistry · 2025Article
- Challenges in Diagnosing Adolescent Goiter: A Case Report with Brief Literature Insights in Juvenile Desmoid-Type Fibromatosis of the Thyroid Gland.Journal of clinical medicine · 2025Review
- Pediatric Desmoid Tumor of the Head and Neck: A Systematic Review and Modified Framework for Management by Age Group.Plastic and reconstructive surgery. Global open · 2024Article
- Real-life experience with sorafenib for advanced and refractory desmoid-type fibromatosis.Acta oncologica (Stockholm, Sweden) · 2024Article
- Article
- Favorable clinical efficacy of cytotoxic chemotherapy in patients with progressive desmoid tumors: a retrospective real-world study.International journal of clinical oncology · 2024Article
- Total Resection of Pediatric Desmoid Tumor of the Left Neck with Utilization of 3D Virtual Surgical Planning.Plastic and reconstructive surgery. Global open · 2024Article
- Paraspinal Desmoid Tumor in a Pediatric Patient with No Surgical History: A Case Report.Asian journal of neurosurgery · 2024Article
- Desmoid Tumors: A Comprehensive Review.Advances in therapy · 2023Review
- Two synchronous desmoids tumours of the thoracic wall: A case report.International journal of surgery case reports · 2023Article
- Recurring desmoid tumor of the neck: A case report.Clinical case reports · 2023Article
- Case report: A rare case of desmoid-type fibromatosis originating in the small intestine.Frontiers in medicine · 2023Article
- Recent Advances and Current Management for Desmoid Tumor Associated with Familial Adenomatous Polyposis.Journal of the anus, rectum and colon · 2023Review
- Dual-phase contrast-enhanced multislice computed tomography scans play a key role in the diagnosis of abdominal wall desmoid-type fibromatoses.Technology and health care : official journal of the European Society for Engineering and Medicine · 2023Article
- Health-related quality of life (HRQoL), anxiety, and depression in patients with desmoid type fibromatosis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementDesmoid-type fibromatosis is a sarcoma subtype that gathers some singular characteristics, making it a difficult challenge to face in clinical practice. Despite its excellent survival prognosis, these tumors may be unpredictable, ranging from an asymptomatic indolent course to persistent, local, and extended recurrences that significantly impair quality of life. Although surgery was initially considered the first elective treatment, collected published data during the past few years are now pointing to the "wait and see" approach as a reasonable initial strategy because many patients can live a long life with the disease without having symptoms. When symptoms appear or there is a risk of functional impairment, a wide spectrum of therapies (local and systemic) can be useful in improving symptoms and controlling the disease. Because of the low incidence of desmoid-type fibromatosis, there is scarce scientific evidence supporting any specific treatment. Nonetheless, if volumetric responses are needed, chemotherapy may be a reasonable early option. However, if long-term control of disease is desirable, hormonal therapy, NSAIDs, and TKIs are the likely treatments of choice. Recent new findings in the biologic development of these tumors, such as the role of Wnt/β-catenin dependent pathway, have shown that the prognostic information provided by specific CTNNB1 gene mutations and other genetic profiles can lead to better methods of selecting patients as candidates for other approaches. Based on recent research, the Notch pathway inhibition in DF is one of the most promising potential targets to explore. As an orphan disease, it is mandatory that as many patients as possible be included in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.